logo
Pediatrix Medical Group 2025 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 6, 2025

Pediatrix Medical Group 2025 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 6, 2025

Business Wire21-04-2025
The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors.
ABOUT PEDIATRIX MEDICAL GROUP
Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group's high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,400 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.
Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company's objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as 'believe,' 'hope,' 'may,' 'anticipate,' 'should,' 'intend,' 'plan,' 'will,' 'expect,' 'estimate,' 'project,' 'positioned,' 'strategy' and similar expressions, and are based on assumptions and assessments made by the Company's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled 'Risk Factors', as well the Company's current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the Company's practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the impact of the Company's termination of its then third-party revenue cycle management provider and transition to a hybrid revenue cycle management model with one or more new third-party service providers, including any transition costs associated therewith; the impact of surprise billing legislation; the effects of economic conditions on the Company's business; the effects of the Affordable Care Act and potential healthcare reform; the Company's relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company's ability to comply with the terms of its debt financing arrangements; the impact of management transitions; the timing and contribution of future acquisitions or organic growth initiatives; the effects of share repurchases; and the effects of the Company's transformation initiatives, including its reorientation on, and growth strategy for, its hospital based and maternal fetal businesses.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Raymond James Raises Infinity Natural Resources (INR) to $29 Amid Q2 Production Growth, Lower Operating Costs
Raymond James Raises Infinity Natural Resources (INR) to $29 Amid Q2 Production Growth, Lower Operating Costs

Yahoo

time18 minutes ago

  • Yahoo

Raymond James Raises Infinity Natural Resources (INR) to $29 Amid Q2 Production Growth, Lower Operating Costs

Infinity Natural Resources Inc. (NYSE:INR) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 22, Raymond James analyst John Freeman raised the firm's price target on Infinity Natural Resources to $29 from $28, while maintaining a Strong Buy rating on the shares. While macro uncertainty remains, the oil prices are recovering, and so Raymond James sees minimal activity changes from management teams. Following this sentiment, Infinity Natural Resources held its Q2 2025 earnings call in August and reported a 25% production increase, with average daily production reaching 33.1 MBOE per day, up from 26.5 MBOE per day in Q1. This was a 28% year-over-year rise in net production due to the successful development of Marcellus Shale wells. A row of massive oil rigs in a desert landscape, against a setting sun. Infinity improved its efficiency, with operating costs per barrel of oil equivalent declining to $7.93 from $8.14 in Q2 2024. It also successfully accelerated a Pennsylvania natural gas project. The company's 2025 production outlook is between 32 and 35 MBOE per day, with capital expenditures for drilling and completion projected at $240 to $280 million, and midstream activities between $9 and $12 million. Infinity Natural Resources Inc. (NYSE:INR) acquires, explores, and develops properties to produce oil, natural gas, and natural gas liquids from underground reservoirs in the US. While we acknowledge the potential of INR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data

This 180 Year-Old Amaro Is Celebrating With A Surrealist New Bottling
This 180 Year-Old Amaro Is Celebrating With A Surrealist New Bottling

Forbes

time21 minutes ago

  • Forbes

This 180 Year-Old Amaro Is Celebrating With A Surrealist New Bottling

Popularly marketed as 'The Bartender's Handshake,' Fernet-Branca is a 180 year-old amaro brand initially sold for medicinal purposes. That cures-what-ails-ya perception even helped keep U.S. sales afloat during Prohibition, when the drink was permitted and legal as a cholera treatment. Unsurprisingly, official claims of medicinal properties have long since vanished, beyond the occasional, cheeky post on the company's self-aware social media. But that's hardly hobbled sales. Today, Fernet-Branca is the world's most recognized brand of fernet, a category of bitter Italian amaro. (Indeed, it's likely Fernet-Branca is the world's most consumed amaro, period.) The brand is especially beloved among bartenders, its trendiness fueled at least in part by a cult online following and savvy social media placement. In recent years, the parent company has also put its weight behind cocktail competitions and other activations seeking to get drinkers enjoying fernet in unconventional ways. Fernet-Branca is also shockingly popular in Argentina, which some estimates suggest accounts for up to 75% of the global consumption. But a new bottling is focused squarely on the U.S. market. To celebrate its 180th anniversary, Fernet-Branca is releasing 49,000 commemorative bottles into the American market, complete with surrealist flair to match its quirky history. Fernet-Branca's 180th Anniversary Limited Edition bottle features an imposing rendition of the brand's famed eagle (which first appeared on the logo in 1901), set against 'a surrealist rendering of the iconic Fratelli Branca distillery in Milan.' Those decorative bottles are sure to stand out on shelves, but the liquid inside remains much the same: 39% ABV (78 proof), characteristically bitter, and made from 27 'herbs, flowers, spices, and roots' the company claims are sourced from 'over four continents.' Company lore also says only one living person knows the exact recipe for the iconic drink, but we do know some likely candidates: rhubarb, myrrh, peppermint, camomile, cinnamon, linden, iris, saffron, and gentian are all confirmed by the manufacturer. After ingredients are infused in the alcohol base, the drink is aged for around one year in oak vats. The 180th Anniversary Limited Edition bottling carries a suggested retail price of $39.99. While it's technically a limited release, those 49,000 bottles are sure to pop up in major markets across the U.S., so don't be surprised to see it on retail shelves—or at your local watering hole, within reach of a veteran bartender looking to share a tipple.

Roth MKM Keeps Their Buy Rating on Talos Energy (TALO)
Roth MKM Keeps Their Buy Rating on Talos Energy (TALO)

Business Insider

timean hour ago

  • Business Insider

Roth MKM Keeps Their Buy Rating on Talos Energy (TALO)

Roth MKM analyst Leo Mariani maintained a Buy rating on Talos Energy today and set a price target of $11.00. The company's shares closed today at $8.20. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Mariani is a top 100 analyst with an average return of 27.3% and a 59.87% success rate. Mariani covers the Energy sector, focusing on stocks such as EOG Resources, Sable Offshore, and EQT. In addition to Roth MKM, Talos Energy also received a Buy from Mizuho Securities's Nitin Kumar CFA in a report issued on August 7. However, today, TR | OpenAI – 4o reiterated a Hold rating on Talos Energy (NYSE: TALO).

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store